Summary of CSPC Pharma (1093.HK) Conference Call Company Overview - **Company**: CSPC Pharma - **Ticker**: 1093.HK - **Industry**: Pharmaceuticals Key Points from the Conference Call Landmark Deal with AstraZeneca - CSPC signed a significant licensing agreement with AstraZeneca (AZN) for the development of long-acting peptide medicine using sustained-release delivery technology and AI-driven peptide drug discovery platform - CSPC will license out the ex-China rights of eight assets, including: - A once-monthly injectable weight management portfolio consisting of SYH2082 (GLP-1/GIP, progressing into phase 1) - Three pre-clinical assets with different mechanisms - Four additional new programs - CSPC will receive an upfront payment of **US$1.2 billion** and potential R&D/sales milestone payments of up to **US$17.3 billion**, plus double-digit royalties on net sales - This marks CSPC's third collaboration with AZN, following previous licensing deals for an Lp(a) inhibitor and AI technology collaboration [1][2] Stock Price Reaction - Following the deal announcement, CSPC's share price closed down by **-10.2%** on January 30, 2026 - Investor sentiment towards the deal was generally positive, citing: - AstraZeneca's focus on cardio-metabolism and sourcing differentiated assets from China - Record-breaking deal size for China-to-West therapeutic agreements - The decline in share price was attributed to high expectations built into the stock price prior to the announcement, with CSPC's share price having increased by **+43%** since December 16, 2025 [2] Long-Acting GLP-1 Class Differentiation - The competition in the GLP-1 class is intensifying, and potential differentiation for latecomers may arise from: - More convenient long-acting dosage forms - Indication differentiation with additional clinical benefits beyond weight loss - Commercial synergy from a comprehensive product portfolio - Leading players in the long-acting GLP-1 agonist space include maridebart cafraglutide (Amgen, in phase 3) and MET-097 (Pfizer, in phase 3) [3][7] Earnings Estimates and Valuation Changes - Earnings estimates for 2026E and 2027E have been revised upwards by **+85.5%** and **+5.3%**, respectively, to account for the upfront payment and potential higher collaboration income - The 12-month price target has been raised to **HK$11.87** from **HK$10.57**, based on a sum-of-the-parts (SOTP) valuation: - DCF-based valuation of **HK$6.7 billion** for NBP - **HK$77.7 billion** for new product wave with global value added for oral GLP-1 - **HK$36.3 billion** for legacy portfolio and generics business - API business valued at **HK$3.9 billion** based on a 4.7x 2026E P/E - The discount rate used for valuation is **9%** [8][9] Risks and Considerations - Key downside risks include: - Earlier-than-expected value-based pricing (VBP) for NBP - Slower-than-expected ramp-up of new products - Failure of major R&D projects - Greater-than-expected price cuts impacting generic drug sales - CSPC maintains a "Buy" rating despite these risks [9][10] Market Context - CSPC's market capitalization is approximately **HK$110.6 billion** (US$14.2 billion) - The company is positioned within the China Pharma & Biotech sector, with a notable M&A rank of **3** [10]

Summary of Key Points from the Conference Call Industry and Company Overview - The conference call primarily discusses the **US Equity Strategy** with a focus on **AI-related themes**, **Pharmaceuticals**, **EU Defense Spending**, and **EU Electrification and Renewables** [2][6][11]. Core Insights and Arguments - **AI Themes**: AI Software Pioneers are currently the preferred investment within AI-related stocks, showing slight month-over-month improvement. However, concerns about the return on AI capital expenditures persist. The REVS framework ranks AI peripherals as the top theme, supported by high earnings momentum and a favorable late-cycle growth regime [6][11]. - **Pharmaceuticals**: The sentiment score for the Pharmaceuticals thematic basket is improving, with negative revisions in US Pharma & Biotech slowing and turning slightly positive. Valuations are under pressure but appear attractive [6][11]. - **EU Defense Spending**: This theme has stabilized in the rankings after previous declines. Earnings revisions had stalled, which is often a concern when stocks are expensive and crowded. Top stocks include Thales, BAE, and Rheinmetall [6][11]. - **EU Electrification and Renewables**: These themes are climbing in the scorecard, marking a reversal from a multi-year downgrade cycle. Factors such as cost inflation and rising rates are abating, which is positive for these sectors [6][11]. - **Consumer Themes**: EU Consumer themes, including Luxury Goods and UK Homebuilders, are at the bottom of the scorecard, although scores are not materially negative. Stabilizing earnings revisions are crucial for these themes to regain attractiveness [6][11]. Additional Important Insights - **Regional Performance**: The Asia region, particularly Japan, ranks strongly among developed markets. Taiwan, Hong Kong, and South Korea also show positive signals. If earnings revisions stabilize or improve, significant outperformance is expected [6][11]. - **European Market Challenges**: Europe ranks below the US due to score dispersion, with tariffs, currency issues, and weak Chinese demand negatively impacting half of the European market. However, top sectors like Telecoms, Utilities, Financials, and Industrials are performing well [6][11]. - **US Market Dynamics**: In the US, momentum is driven by preferred themes such as AI, Reshoring, and Financials. Earnings revisions are positive, and valuation concerns are not extreme. Consumer Cyclicals and Low-Income Consumer themes have improved due to positive earnings revisions [11][21]. - **Defensive Positioning**: In anticipation of potential stagflation, Health Care vs. Consumer Staples is suggested as a defensive strategy. Relative valuations have improved but remain below historical averages [11][21]. Thematic Rankings and Stock Performance - **Top Scoring Stocks**: Notable stocks in high-scoring themes include MongoDB, Meta, Mastec, Primoris, and Snowflake, with strong earnings revisions and positive sentiment [12][14]. - **Bottom Scoring Stocks**: Stocks in weaker themes include Gerresheimer AG and Salmar ASA, which are experiencing negative earnings revisions and low sentiment scores [15]. Conclusion - The conference call highlights a complex landscape for investors, with strong opportunities in AI and Pharmaceuticals, while caution is advised in consumer sectors and certain European markets. The REVS framework provides a structured approach to assess these themes and identify potential investment opportunities.

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **China A-shares market** and its performance in July 2025, highlighting solid price gains across various sectors [1][2]. Core Insights and Arguments - **Sector Performance**: - **Healthcare**: Led with a **13.5%** increase in July and **23.1%** year-to-date (YTD) performance, driven by recovering demand and strong drug pipelines [2][8]. - **IT**: Increased by **6.7%** in July and **14.7%** YTD, benefiting from Nvidia's resumption of sales to China [2][8]. - **Materials**: Gained **6.4%** in July and **18.0%** YTD, supported by government initiatives against overcapacity [2][9]. - **Energy**: Saw a **4.7%** increase in July but a decline of **1.8%** YTD [2]. - **Real Estate**: Increased by **4.5%** in July but declined **2.3%** YTD [2]. - **Financials**: Only **2.1%** increase in July and **10.5%** YTD, with some companies experiencing significant declines [2][10]. - **Market Drivers**: - The **CSI300** index rose **3.5%** in July, with improving liquidity and solid GDP growth of **5.2%** year-on-year (y-y) in Q2 2025 [5][39]. - **Net inflows** into A-shares totaled **US$193 million**, primarily in Financials, IT, and Materials, while Industrials and Consumer Discretionary saw outflows [5][14]. - **Macroeconomic Indicators**: - **GDP Growth**: China's GDP growth was **5.2%** y-y, with nominal GDP growth at **3.9%** y-y, indicating a decline in the GDP deflator to **-1.2%** [5][39]. - **Industrial Production**: Increased by **6.8%** y-y, with notable growth in high-tech sectors [5][42]. - **Retail Sales**: Grew by **4.8%** y-y, below expectations, indicating weak consumer sentiment [5][39]. - **Trade**: Exports rose **5.8%** y-y, with a rebound in exports to the US [5][41]. Additional Important Insights - **Margin Financing**: The margin buying as a percentage of A-share turnover rose to **10.5%** at the end of July from **9.6%** at the end of June, indicating increased investor confidence [5][24]. - **Fund Issuance**: Equity mutual fund issuance remained stable at **Rmb18 billion** in July, compared to **Rmb21 billion** in June [5][27]. - **Shareholding Structure**: By the end of 2024, retail investors held **42%**, controlling shareholders **43%**, domestic financial institutions **12%**, and foreign investors **3%** of A-shares' total market cap [5][28]. This summary encapsulates the key points from the conference call, providing a comprehensive overview of the current state of the China A-shares market and its underlying economic factors.